By Bill Galluccio Apr 12, 2021 Regeneron announced that the results of a Phase 3 clinical trial show that its antibody cocktail helps prevent symptomatic COVID-19 infections. The company said that the drug, named REGEN-COV, reduced the risk of symptomatic infections by 81%. The drug cocktail was granted an emergency use authorization by the Food and Drug Administration to treat high-risk, non-hospitalized patients with mild to moderate symptoms of COVID-19. That treatment was only approved to be given intravenously. "COVID-19 transmission often occurs via infected people who do not yet have symptoms, so it is critical that we rapidly diagnose and treat these individuals for their own health and to prevent transmission," said